Holen Sie sich die Stockscreener-App
42.95
2.75%
1.15
Handel nachbörslich:
42.84
-0.11
-0.26%
Schlusskurs vom Vortag:
$41.80
Offen:
$42.12
24-Stunden-Volumen:
6.76M
Relative Volume:
2.21
Marktkapitalisierung:
$102.81B
Einnahmen:
$49.41B
Nettoeinkommen (Verlust:
$5.59B
KGV:
17.99
EPS:
2.3875
Netto-Cashflow:
$8.32B
1W Leistung:
+1.34%
1M Leistung:
-2.72%
6M Leistung:
-11.39%
1J Leistung:
-11.21%
1-Tages-Spanne:
$42.12
$42.98
1-Wochen-Bereich:
$40.89
$42.98
52-Wochen-Spanne:
$40.89
$52.68
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
42.95 | 100.06B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,208.12 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 589.48B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 429.58B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 309.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 295.98B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2026-01-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-12-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
662283 Forecast — Price Target — Prediction for 2027 - TradingView
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Press Release: Sanofi Foundation opens new chapter centered on future generations - GlobeNewswire Inc.
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - Ad-hoc-news.de
Muted Sanofi hits fresh 52-week low, shares trade well below analyst targets - Ad-hoc-news.de
Form 6K Sanofi ADR For: 22 June By Investing.com - Investing.com Australia
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals - ChartMill
Sanofi S.A. Stock (FR0000127771): Deutsche Bank trims target but sticks with Buy - Ad-hoc-news.de
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sahm
Sanofi S.A. Stock (FR0000120578): FDA accelerated approval for Tzield puts diabetes franchise in foc - Ad-hoc-news.de
Sanofi S.A. Stock (FR0000120578): Valuation Metrics Under the Microscope - Ad-hoc-news.de
Sanofi S.A. Stock (FR0000127771): Stock in focus as no fresh trigger is verified - Ad-hoc-news.de
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Sanofi S.A. stock (FR0000127771): Diabetes focus and pipeline news keep Big Pharma in motion - Ad-hoc-news.de
European ADRs Started The Week In The Green - Finimize
Sanofi S.A. stock (FR0000127771): diabetes deal and pipeline focus move into the spotlight - AD HOC NEWS
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative - Sahm
Senior Chinese legislator meets Myanmar's foreign minister - news.cgtn.com
Sanofi (SASY) Stock: Pharma Giant Launches AI Sales Agent Built on Snowflake - MEXC
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi S.A. stock (FR0000120578): analyst consensus steady as ADRs trade in low-40s USD range - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Analyst consensus points to hold stance as shares hover in low-40s - Ad-hoc-news.de
Sanofi S.A. stock (FR0000127771): Technical picture and price action on Euronext Paris - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Vaccine and obesity focus after Q1 2026 earnings - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 results, pipeline focus and outlook for US investors - Ad-hoc-news.de
SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals - ChartMill
Publicis Groupe stock (FR0000120578): LiveRamp deal and AI push keep investors focused - AD HOC NEWS
Publicis Groupe S.A. stock (FR0000120578): LiveRamp deal and AI push reshape data strategy - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): EU green light for multiple myeloma drug Sarclisa draws investor f - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Vaccine unit and new drug launches keep investors alert - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 beat and pipeline focus keep investors watching - Ad-hoc-news.de
Sanofi stock (FR0000120578): Pipeline updates keep investors watching - Ad-hoc-news.de
Sanofi stock (FR0000120578): trial data and EU approval updates - AD HOC NEWS
Sanofi stock (FR0000120578): Dupixent data and AI investment keep focus on growth - AD HOC NEWS
Sanofi stock (FR0000120578): FDA, dividend and Dupixent keep investors focused - Ad-hoc-news.de
Sanofi S.A. stock (FR0000127771): Q1 figures, GLP-1 hopes and focus on pipeline value - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 2026 results reviewed - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Global pharma leader's business and market position - AD HOC NEWS
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):